Eli Lilly and Company (NYSE:LLY) Stock Position Lifted by Proactive Wealth Strategies LLC

Proactive Wealth Strategies LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 184.2% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,256 shares of the company’s stock after purchasing an additional 814 shares during the quarter. Proactive Wealth Strategies LLC’s holdings in Eli Lilly and Company were worth $969,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently modified their holdings of LLY. AMF Tjanstepension AB grew its stake in shares of Eli Lilly and Company by 113.7% in the third quarter. AMF Tjanstepension AB now owns 331,786 shares of the company’s stock worth $293,964,000 after purchasing an additional 176,552 shares in the last quarter. Values Added Financial LLC boosted its stake in Eli Lilly and Company by 4.9% during the third quarter. Values Added Financial LLC now owns 366 shares of the company’s stock valued at $324,000 after buying an additional 17 shares in the last quarter. Trilogy Capital Inc. boosted its stake in Eli Lilly and Company by 3.9% during the third quarter. Trilogy Capital Inc. now owns 1,347 shares of the company’s stock valued at $1,193,000 after buying an additional 51 shares in the last quarter. James Hambro & Partners LLP boosted its stake in Eli Lilly and Company by 3.7% during the third quarter. James Hambro & Partners LLP now owns 340 shares of the company’s stock valued at $301,000 after buying an additional 12 shares in the last quarter. Finally, Bluesphere Advisors LLC boosted its stake in Eli Lilly and Company by 1.7% during the third quarter. Bluesphere Advisors LLC now owns 966 shares of the company’s stock valued at $856,000 after buying an additional 16 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 1.6 %

Shares of Eli Lilly and Company stock opened at $857.38 on Wednesday. The stock has a 50-day moving average price of $796.41 and a 200 day moving average price of $845.73. The company has a market cap of $813.93 billion, a P/E ratio of 73.22, a P/E/G ratio of 1.87 and a beta of 0.42. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a 1 year low of $711.40 and a 1 year high of $972.53.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 86.26% and a net margin of 23.51%. As a group, analysts expect that Eli Lilly and Company will post 23.33 EPS for the current fiscal year.

Eli Lilly and Company declared that its Board of Directors has authorized a stock repurchase program on Monday, December 9th that permits the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization permits the company to repurchase up to 2% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s board of directors believes its stock is undervalued.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 14th will be given a $1.50 dividend. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a yield of 0.70%. The ex-dividend date is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio is presently 51.24%.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Truist Financial raised their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research note on Monday, February 3rd. Wolfe Research assumed coverage on Eli Lilly and Company in a research note on Friday, November 15th. They set an “outperform” rating and a $1,000.00 target price for the company. Citigroup decreased their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Redburn Atlantic raised Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Four analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $997.50.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.